Organon & (US:OGN) ZACKSยท2025-05-01 15:35Core Insights - Organon reported $1.51 billion in revenue for Q1 2025, a year-over-year decline of 6.7% and an EPS of $1.02 compared to $1.22 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $1.52 billion, resulting in a surprise of -0.73%, while the EPS exceeded expectations by 14.61% [1] Revenue Breakdown - Revenue from Established Brands-International-Respiratory-Dulera was $10 million, below the estimated $12.32 million, reflecting a -23.1% change year-over-year [4] - Revenue from Established Brands-International-Respiratory-Clarinex was $34 million, slightly below the estimate of $34.23 million, showing a -5.6% change year-over-year [4] - Revenue from Women's Health-International-NuvaRing was $16 million, below the estimated $17.23 million, representing a -27.3% change year-over-year [4] - Revenue from Women's Health-U.S.-NuvaRing was $6 million, compared to the estimated $8.12 million, indicating a -62.5% year-over-year change [4] - Revenue from Women's Health-Nexplanon/Implanon NXT was $248 million, exceeding the estimate of $234.36 million, with a +12.7% change year-over-year [4] - Revenue from Women's Health-Follistim AQ was $69 million, surpassing the estimate of $55.63 million, reflecting a +50% change year-over-year [4] - Total revenue from Established Brands was $887 million, below the estimated $918.89 million, showing an -11.4% change year-over-year [4] - Total revenue from Biosimilars was $141 million, slightly below the estimate of $144.88 million, representing a -17.1% change year-over-year [4] - Total revenue from Women's Health was $463 million, exceeding the estimate of $435.11 million, with a +9.7% change year-over-year [4] - Total revenue from Other was $22 million, below the estimated $25.18 million, indicating a -24.1% change year-over-year [4] - Revenue from Women's Health-NuvaRing was $22 million, below the estimated $24.64 million, reflecting a -42.1% change year-over-year [4] - Revenue from Biosimilars-Renflexis was $57 million, slightly above the estimate of $53.74 million, showing a -17.4% change year-over-year [4] Stock Performance - Shares of Organon have returned -12.2% over the past month, compared to the Zacks S&P 500 composite's -0.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]